Trial of Paclitaxel Plus Gemcitabine and Cisplatin in Bladder Cancer
Status:
Terminated
Trial end date:
2017-09-14
Target enrollment:
Participant gender:
Summary
This trial is for people with bladder cancer that has spread. The purpose of this research
study is to see if the chemotherapy combination of gemcitabine and cisplatin plus paclitaxel
is safe and effective treatment for bladder cancer.
Paclitaxel, gemcitabine and cisplatin have all been approved by the United States Food and
Drug Administration (FDA). Gemcitabine and cisplatin is a standard treatment for bladder
cancer. There have been studies that show that paclitaxel and cisplatin have antitumor
activity in bladder cancer. European researchers studied paclitaxel, gemcitabine and
cisplatin (same drug combination in this trial) and found that the combination provided good
disease control and was well tolerated. Investigators are studying the same drug combination,
but at different dosages and schedule.
Phase:
Phase 2
Details
Lead Sponsor:
The University of Texas Health Science Center, Houston